Skip to main content
Premium Trial:

Request an Annual Quote

Almac, OncoMed to Develop CDx for R-Spondin 3

NEW YORK (GenomeWeb) – Almac Diagnostics and OncoMed Pharmaceuticals will develop a companion diagnostic test to predict patient response to a new therapeutic under development by OncoMed. 

Under the agreement announced today, Almac will develop the test for the drug targeting the R-Spondin 3 (RSPO3) gene. The company said that anti-RSPO3 has demonstrated activity in preclinical models against various major tumor types, including colon, lung, and ovarian cancers, and the partners are developing a gene expression RSPO3 CLIA assay to select patients in the clinical development of the drug. 

OncoMed has filed an investigational new drug application for anti-RSPO3 with the US Food and Drug Administration and plans to start a Phase Ia clinical trial during the summer. 

"This companion diagnostic development program is a significant milestone in our work together and helps Almac achieve its goal of advancing human health globally," Paul Harkin, president of Almac's Diagnostic business unit, said in a statement. 

Financial and other terms of the deal were not disclosed.

The Scan

Foxtail Millet Pangenome, Graph-Based Reference Genome

Researchers in Nature Genetics described their generation of a foxtail millet pangenome, which they say can help in crop trait improvement.

Protein Length Distribution Consistent Across Species

An analysis in Genome Biology compares the lengths of proteins across more than 2,300 species, finding similar length distributions.

Novel Genetic Loci Linked to Insulin Resistance in New Study

A team reports in Nature Genetics that it used glucose challenge test data to home in on candidate genes involved in GLUT4 expression or trafficking.

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.